Peter Hecht has served as Ironwood’s CEO and a director since co‐founding the company in 1998. He started Ironwood because he was attracted to “the idea of working with a team of people who challenge, inspire and humble me,” and building an enduring organization dedicated to creating important medicines. Under his leadership, Ironwood has grown from nine Ph.D. scientists to a fully‐integrated research, development and commercial organization. Prior to founding Ironwood, Peter was a research fellow at Whitehead Institute for Biomedical Research, an affiliate of Massachusetts Institute of Technology (MIT). He earned his Ph.D. in molecular biology from the University of California at Berkeley as well as a B.S. in mathematics and an M.S. in biology from Stanford University.
Lisa Adler joined Ironwood in 2014, drawn by the opportunity to apply her 25 years of experience in corporate branding and healthcare communications to help shape our corporate story and the way we engage with external audiences, such as media and investors, as well as with our employees. Lisa most recently served as vice president of corporate communications at Millennium Pharmaceuticals, now a part of Takeda Pharmaceutical Company Ltd. While at Millennium, she designed and implemented global communications strategies, overseeing corporate reputation management, brand public relations, digital communications, investor relations, corporate social responsibility, patient advocacy and employee communications. Prior to joining Millennium, Lisa held communications positions with Feinstein Kean Healthcare, a public relations agency and an Ogilvy PR Worldwide company, as well as with Johnson & Johnson. She holds a B.S. from the University of Massachusetts at Amherst.
Brian Cali co‐founded Ironwood in 1998 and has served as Senior Vice President of Preclinical Research and Development (R&D) since 2010. He is focused on helping the R&D organization execute on its strategy to advance an exciting pipeline of new product candidates, building on the science team’s core expertise in gastrointestinal disorders and guanylate cyclase pathways. Prior to this role, Brian oversaw program management, helping to ensure effective leadership for cross‐functional research and development teams, as well as product alliances. Before founding Ironwood, Brian was the Chiron fellow of the Life Sciences Research Foundation at Whitehead Institute for Biomedical Research. He holds a Ph.D. in cellular and molecular biology from the University of Wisconsin–Madison and earned a B.S. in microbiology from Cornell University.
Mark Currie has led Ironwood’s R&D efforts since joining Ironwood in 2002. He co‐discovered the natural hormones (guanylin and uroguanylin) that activate guanylate cyclase‐C (GC‐C), a target thought to be useful in the treatment of a number of gastrointestinal diseases, and he brought a unique understanding of GC‐C pharmacology to Ironwood. This expertise in GC‐C and related cGMP pathways supported our team’s discovery and development of our first medicine. Prior to joining Ironwood, Mark directed cardiovascular and central nervous system disease research as vice president of discovery research at Sepracor, Inc. He also initiated, built and led discovery pharmacology and served as director of arthritis and inflammation at Monsanto Company, leading an effort that resulted in marketed Cox‐2 inhibitors for the treatment of pain in humans and animals. Mark earned a Ph.D. in cell biology from the Bowman‐Gray School of Medicine of Wake Forest University and a B.S. in biology from the University of South Alabama.
Halley Gilbert joined Ironwood in 2008 as the founding member of our legal department. Halley describes her role as “balancing strategic, operational and legal considerations to help my colleagues and the company meet our short‐ and long‐term corporate goals.” With previous positions as vice president and deputy general counsel of Cubist Pharmaceuticals, Inc., and corporate counsel of Genzyme Corp., Halley brings expertise in corporate transactions, corporate governance, compliance, employment law and other legal and operational issues relevant to launching new medicines into both specialty and primary care markets. Halley’s legal career began at Skadden, Arps, Slate, Meagher & Flom LLP, where she specialized in mergers and acquisitions and securities law. She received her J.D. from Northwestern University School of Law and a B.A. from Tufts University.
Tom Graney joined Ironwood in 2014, bringing experience in finance, accounting and corporate strategy gained during his 20 years of service with Johnson & Johnson and its affiliates. He most recently served for four years as worldwide vice president of finance and chief financial officer of Johnson & Johnson’s Ethicon, a global leader in surgical medical devices. In addition, Tom has extensive global experience that spans corporate development, commercial strategy, portfolio management and supply chain management. A Chartered Financial Analyst charterholder, Tom holds a B.S. in accounting from the University of Delaware and an M.B.A. in marketing, finance and international business from the Leonard N. Stern School of Business at New York University.
Michael Hall joined Ironwood in 2013, bringing his drug development experience, scientific knowledge, patient‐oriented medical perspective, and proven leadership capabilities to our clinical development team. He was attracted to Ironwood by the “discipline with which the team advances programs and the degree to which they focus on science that addresses unmet needs of patients.” Previously Michael served as chief medical officer and senior vice president at Repligen Corp. and before that as vice president of global clinical affairs at Shire Human Genetic Therapies Inc. He has also held medical affairs, pharmacovigilance and clinical positions at Novartis Pharmaceuticals Corp. Michael began his career as a physician at Hillbrow Hospital and Johannesburg General Hospital, both in Johannesburg. He earned his MB. BCh. medical degree from the University of Witwatersrand Medical School in Johannesburg.
Senior Vice President, Marketing & Sales
Tom McCourt joined Ironwood as chief commercial officer and senior vice president of marketing and sales in 2009. He was drawn to Ironwood by the quality and values of the people and by the potential he saw in our first product. Since coming on board, Tom has designed and implemented Ironwood’s commercial strategy, leading the hiring of a sales force and bringing our first medicine to patients. Prior to joining Ironwood, Tom led the U.S. brand team for denosumab at Amgen Inc. Before that, he held a number of senior commercial roles with Novartis AG, where he directed the launch and growth of Zelnorm® (tegaserod maleate) for the treatment of patients with IBS‐C and chronic constipation and held a number of senior commercial roles, including vice president of strategic marketing and operations. Tom was also part of the founding team at Astra Merck Inc., leading the development of the medical affairs and science liaison group and serving as brand manager for Prilosec® (omeprazole). He has a degree in pharmacy from the University of Wisconsin.
Jonathan Rosin joined Ironwood as head of human resources in early 2012. He’s committed to building and developing Ironwood’s team as well as supporting a collaborative environment. Jonathan brings to Ironwood more than 20 years of experience in talent management, organizational development and leadership. Most recently, he was vice president of talent management at Fidelity Investments, and before that, director of leadership and organizational development at Genzyme Corp. Jonathan previously spent eight years with the Forum Corp., a talent and customer experience consulting firm supporting multiple industries. Born in South Africa, Jonathan graduated as a clinical psychologist from the University of Cape Town.